Literature DB >> 25732096

The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains.

Nicole Büscher1, Christina Paulus, Michael Nevels, Stefan Tenzer, Bodo Plachter.   

Abstract

The morphogenesis of human cytomegalovirus (HCMV) particles is incompletely understood. Analysis of the protein composition of HCMV virions and subviral dense bodies (DBs) by mass spectrometry provides valuable information to increase our knowledge about viral morphogenesis. Here we addressed the viral proteome of virions and DBs from two fibroblast-passaged isolates and the widely used endotheliotropic TB4-BAC40 strain of HCMV. The results show a striking concordance of the particle proteomes of different strains. One surprising finding was that only low levels of gpUL128-131A were found in TB40-BAC4 virions. These three proteins, together with gH and gL, form a protein complex that is critical for the endothelial cell tropism of that strain. This indicates that either few molecules of that complex per virion or a small fraction of pentamer-positive virions suffice to retain the tropism. Furthermore, using a pp65-deficient variant of TB40-BAC4, we confirm our previous finding that the major tegument protein serves as a scaffold to support the upload of a fraction of the outer tegument proteins into particles. The results demonstrate that HCMV particle morphogenesis is an orchestrated process that leads to the formation of particles with a largely strain-independent protein composition.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25732096     DOI: 10.1007/s00430-015-0397-y

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  42 in total

Review 1.  Viral proteomics.

Authors:  Karen L Maxwell; Lori Frappier
Journal:  Microbiol Mol Biol Rev       Date:  2007-06       Impact factor: 11.056

2.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

3.  Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

Authors:  Giuseppe Gerna; Elena Percivalle; Daniele Lilleri; Laura Lozza; Chiara Fornara; Gabriele Hahn; Fausto Baldanti; M Grazia Revello
Journal:  J Gen Virol       Date:  2005-02       Impact factor: 3.891

4.  Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies.

Authors:  Anna Kabanova; Laurent Perez; Daniele Lilleri; Jessica Marcandalli; Gloria Agatic; Simone Becattini; Silvia Preite; Dario Fuschillo; Elena Percivalle; Federica Sallusto; Giuseppe Gerna; Davide Corti; Antonio Lanzavecchia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

5.  Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.

Authors:  Thomas Herget; Martina Freitag; Monika Morbitzer; Regina Kupfer; Thomas Stamminger; Manfred Marschall
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Nucleosome maps of the human cytomegalovirus genome reveal a temporal switch in chromatin organization linked to a major IE protein.

Authors:  Einat Zalckvar; Christina Paulus; Desiree Tillo; Alexandra Asbach-Nitzsche; Yaniv Lubling; Carla Winterling; Nicholas Strieder; Katrin Mücke; Felicia Goodrum; Eran Segal; Michael Nevels
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

7.  Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo.

Authors:  Daniele Lilleri; Anna Kabanova; Antonio Lanzavecchia; Giuseppe Gerna
Journal:  J Clin Immunol       Date:  2012-07-27       Impact factor: 8.317

8.  Human cytomegalovirus major immediate early 1 protein targets host chromosomes by docking to the acidic pocket on the nucleosome surface.

Authors:  Katrin Mücke; Christina Paulus; Katharina Bernhardt; Katrin Gerrer; Kathrin Schön; Alina Fink; Eva-Maria Sauer; Alexandra Asbach-Nitzsche; Thomas Harwardt; Bärbel Kieninger; Werner Kremer; Hans Robert Kalbitzer; Michael Nevels
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

9.  Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.

Authors:  Yingxia Wen; James Monroe; Christine Linton; Jacob Archer; Clayton W Beard; Susan W Barnett; Giuseppe Palladino; Peter W Mason; Andrea Carfi; Anders E Lilja
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

10.  HCMV spread and cell tropism are determined by distinct virus populations.

Authors:  Laura Scrivano; Christian Sinzger; Hans Nitschko; Ulrich H Koszinowski; Barbara Adler
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

View more
  19 in total

1.  Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.

Authors:  Flavia Chiuppesi; Teodora Kaltcheva; Zhuo Meng; Peter A Barry; Don J Diamond; Felix Wussow
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

2.  Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Yi Liu; Zhaoti Wang; Alivelu Irrinki; Floro Cataniag; Nga Nguyen; Stacie Lambert; Hui Liu; Shahin Aslam; Greg Duke; Michael P McCarthy; Louise McCormick
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.

Authors:  Caroline Lehmann; Jessica Julia Falk; Nicole Büscher; Inessa Penner; Christine Zimmermann; Patricia Gogesch; Christian Sinzger; Bodo Plachter
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

4.  Human Cytomegalovirus US28 Is Important for Latent Infection of Hematopoietic Progenitor Cells.

Authors:  Monica S Humby; Christine M O'Connor
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

5.  Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.

Authors:  Flavia Chiuppesi; Felix Wussow; Erica Johnson; Chao Bian; Meng Zhuo; Augustine Rajakumar; Peter A Barry; William J Britt; Rana Chakraborty; Don J Diamond
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

6.  The Abundant Tegument Protein pUL25 of Human Cytomegalovirus Prevents Proteasomal Degradation of pUL26 and Supports Its Suppression of ISGylation.

Authors:  Christine Zimmermann; Nicole Büscher; Steffi Krauter; Nadine Krämer; Uwe Wolfrum; Elisabeth Sehn; Stefan Tenzer; Bodo Plachter
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

7.  A Viral Pilot for HCMV Navigation?

Authors:  Barbara Adler
Journal:  Viruses       Date:  2015-07-15       Impact factor: 5.048

Review 8.  Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells.

Authors:  Felix Wussow; Flavia Chiuppesi; Heidi Contreras; Don J Diamond
Journal:  Vaccines (Basel)       Date:  2017-10-31

9.  Chimeric Antigen Receptors Targeting Human Cytomegalovirus.

Authors:  Ayub Ali; Flavia Chiuppesi; Minh Nguyen; Mary Ann Hausner; Jenny Nguyen; Mindy Kha; Angelina Iniguez; Felix Wussow; Don J Diamond; Otto O Yang
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

Review 10.  Mutual Interference between Cytomegalovirus and Reconstitution of Protective Immunity after Hematopoietic Cell Transplantation.

Authors:  Matthias J Reddehase
Journal:  Front Immunol       Date:  2016-08-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.